We used treatment with
intra-arterial injection in cases of liver and peritoneal
metastasis in progressive or recurrent
gastric cancer patients. The investigation of the relationship between efficiency of
therapy and survival period was evaluated. The effective rate of sequential treatment of peritoneal
metastasis with MTX.5-FU in 34 cases was 35.3%, while that of liver
metastasis with MMC combined with DSM in 12 cases was 50%. Although the effective rate among 16 cases treated with MMC.5-FU combined with
Angiotensin II was 50%, no effect was recognized in the groups treated with AF and MF. In cases of peritoneal
metastasis with MTX.5-FU, the prognosis PR cases was significantly better than that of NC.PD. For treatment of liver
metastasis with MMC combined with DSM and MMC.5-FU combined with
Angiotensin II, the PR prognosis was unsatisfactory and the survival period did not significantly improve compared with that of NC.PD. In future cases of liver
metastasis, these results indicate the extreme difficulty in maintaining
therapy and controlling the lesion after PR. We speculated that sequential treatment of peritoneal
metastasis with MTX.5-FU was useful because it significantly extended the survival period in PR cases.